Research ExplorerPublicationsOpposite roles of FOXA1 and NKX2-1 in lung cancer progressio...

Opposite roles of FOXA1 and NKX2-1 in lung cancer progression.

Standard

Opposite roles of FOXA1 and NKX2-1 in lung cancer progression. / Deutsch, Lena; Wrage, Michaela; Koops, Susan; Glatzel, Markus; Uzunoglu, Faik Güntac; Kutup, Asad; Hinsch, Andrea; Sauter, Guido; Izbicki, Jakob R.; Pantel, Klaus; Wikman, Harriet.

In: GENE CHROMOSOME CANC, Vol. 51, No. 6, 6, 2012, p. 618-629.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Deutsch, L, Wrage, M, Koops, S, Glatzel, M, Uzunoglu, FG, Kutup, A, Hinsch, A, Sauter, G, Izbicki, JR, Pantel, K & Wikman, H 2012, 'Opposite roles of FOXA1 and NKX2-1 in lung cancer progression.', GENE CHROMOSOME CANC, vol. 51, no. 6, 6, pp. 618-629. <http://www.ncbi.nlm.nih.gov/pubmed/22383183?dopt=Citation>

APA

Deutsch, L., Wrage, M., Koops, S., Glatzel, M., Uzunoglu, F. G., Kutup, A., Hinsch, A., Sauter, G., Izbicki, J. R., Pantel, K., & Wikman, H. (2012). Opposite roles of FOXA1 and NKX2-1 in lung cancer progression. GENE CHROMOSOME CANC, 51(6), 618-629. [6]. http://www.ncbi.nlm.nih.gov/pubmed/22383183?dopt=Citation

Vancouver

Deutsch L, Wrage M, Koops S, Glatzel M, Uzunoglu FG, Kutup A et al. Opposite roles of FOXA1 and NKX2-1 in lung cancer progression. GENE CHROMOSOME CANC. 2012;51(6):618-629. 6.

Bibtex

@article{f1f64dadb6024d1fac58fd0cc7718d5d,
title = "Opposite roles of FOXA1 and NKX2-1 in lung cancer progression.",
abstract = "Gene copy number profiles of primary lung tumors were screened for high-level amplifications. We detected 22 high-level amplifications in various loci, including 14q13. This locus is known to harbor the adenocarcinoma (AC) lineage-specific target gene NKX2-1, which is not expressed in squamous cell carcinoma (SCC). As the 14q amplification was also found in SCC, we investigated whether or not FOXA1 might be the corresponding target gene for SCC. Focusing on these two target genes, we assessed gene amplifications and protein expression of NKX2-1 and FOXA1 in primary lung tumors (n = 554) and brain metastases (n = 68). Primary AC (n = 194) showed positive protein expression of NKX2-1 in 58.2% of the samples compared with 4.2% of primary SCC samples (n = 212). Positive staining for FOXA1 was seen in 34.7% of the SCC samples, which was comparable with 39.6% in the AC samples. For brain metastases, FOXA1 expression was slightly higher in the SCC samples (55.6%) compared with the non-matched primary SCC tumor samples (43.4%), whereas NKX2-1 expression was comparable in both primary tumors and brain metastases. Positive FOXA1 and NKX2-1 expression was associated with a gain or amplification in 34.6% and 28.6% of cases, respectively. The expression of NKX2-1 was associated with early stage and grade among the AC cases. In contrast, FOXA1 expression in SCC was associated with distant metastases as well as an unfavorable survival rate (P = 0.039). These results suggest that both FOXA1 and NKX2-1 may act as lineage-specific target genes within the 14q amplicon with opposite functions in lung cancer.",
author = "Lena Deutsch and Michaela Wrage and Susan Koops and Markus Glatzel and Uzunoglu, {Faik G{\"u}ntac} and Asad Kutup and Andrea Hinsch and Guido Sauter and Izbicki, {Jakob R.} and Klaus Pantel and Harriet Wikman",
year = "2012",
language = "English",
volume = "51",
pages = "618--629",
journal = "GENE CHROMOSOME CANC",
issn = "1045-2257",
publisher = "Wiley-Liss Inc.",
number = "6",

}

RIS

TY - JOUR

T1 - Opposite roles of FOXA1 and NKX2-1 in lung cancer progression.

AU - Deutsch, Lena

AU - Wrage, Michaela

AU - Koops, Susan

AU - Glatzel, Markus

AU - Uzunoglu, Faik Güntac

AU - Kutup, Asad

AU - Hinsch, Andrea

AU - Sauter, Guido

AU - Izbicki, Jakob R.

AU - Pantel, Klaus

AU - Wikman, Harriet

PY - 2012

Y1 - 2012

N2 - Gene copy number profiles of primary lung tumors were screened for high-level amplifications. We detected 22 high-level amplifications in various loci, including 14q13. This locus is known to harbor the adenocarcinoma (AC) lineage-specific target gene NKX2-1, which is not expressed in squamous cell carcinoma (SCC). As the 14q amplification was also found in SCC, we investigated whether or not FOXA1 might be the corresponding target gene for SCC. Focusing on these two target genes, we assessed gene amplifications and protein expression of NKX2-1 and FOXA1 in primary lung tumors (n = 554) and brain metastases (n = 68). Primary AC (n = 194) showed positive protein expression of NKX2-1 in 58.2% of the samples compared with 4.2% of primary SCC samples (n = 212). Positive staining for FOXA1 was seen in 34.7% of the SCC samples, which was comparable with 39.6% in the AC samples. For brain metastases, FOXA1 expression was slightly higher in the SCC samples (55.6%) compared with the non-matched primary SCC tumor samples (43.4%), whereas NKX2-1 expression was comparable in both primary tumors and brain metastases. Positive FOXA1 and NKX2-1 expression was associated with a gain or amplification in 34.6% and 28.6% of cases, respectively. The expression of NKX2-1 was associated with early stage and grade among the AC cases. In contrast, FOXA1 expression in SCC was associated with distant metastases as well as an unfavorable survival rate (P = 0.039). These results suggest that both FOXA1 and NKX2-1 may act as lineage-specific target genes within the 14q amplicon with opposite functions in lung cancer.

AB - Gene copy number profiles of primary lung tumors were screened for high-level amplifications. We detected 22 high-level amplifications in various loci, including 14q13. This locus is known to harbor the adenocarcinoma (AC) lineage-specific target gene NKX2-1, which is not expressed in squamous cell carcinoma (SCC). As the 14q amplification was also found in SCC, we investigated whether or not FOXA1 might be the corresponding target gene for SCC. Focusing on these two target genes, we assessed gene amplifications and protein expression of NKX2-1 and FOXA1 in primary lung tumors (n = 554) and brain metastases (n = 68). Primary AC (n = 194) showed positive protein expression of NKX2-1 in 58.2% of the samples compared with 4.2% of primary SCC samples (n = 212). Positive staining for FOXA1 was seen in 34.7% of the SCC samples, which was comparable with 39.6% in the AC samples. For brain metastases, FOXA1 expression was slightly higher in the SCC samples (55.6%) compared with the non-matched primary SCC tumor samples (43.4%), whereas NKX2-1 expression was comparable in both primary tumors and brain metastases. Positive FOXA1 and NKX2-1 expression was associated with a gain or amplification in 34.6% and 28.6% of cases, respectively. The expression of NKX2-1 was associated with early stage and grade among the AC cases. In contrast, FOXA1 expression in SCC was associated with distant metastases as well as an unfavorable survival rate (P = 0.039). These results suggest that both FOXA1 and NKX2-1 may act as lineage-specific target genes within the 14q amplicon with opposite functions in lung cancer.

M3 - SCORING: Journal article

VL - 51

SP - 618

EP - 629

JO - GENE CHROMOSOME CANC

JF - GENE CHROMOSOME CANC

SN - 1045-2257

IS - 6

M1 - 6

ER -